Get the Stockscreener App
7.52
0.94%
0.07
After Hours:
8.05
0.53
+7.05%
Precision Biosciences Inc stock is traded at $7.52, with a volume of 331.84K.
It is up +0.94% in the last 24 hours and up +25.12% over the past month.
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).
See More
Previous Close:
$7.45
Open:
$7.46
24h Volume:
331.84K
Relative Volume:
1.24
Market Cap:
$194.04M
Revenue:
$34.26M
Net Income/Loss:
$-46.61M
P/E Ratio:
-1.4516
EPS:
-5.1806
Net Cash Flow:
$-62.01M
1W Performance:
+8.99%
1M Performance:
+25.12%
6M Performance:
+16.77%
1Y Performance:
+47.45%
1-Day Range:
$7.39
$8.0598
1-Week Range:
$6.50
$8.0598
52-Week Range:
$3.53
$8.82
Precision Biosciences Inc Stock (DTIL) Company Profile
Name
Precision Biosciences Inc
Sector
Industry
Phone
919-314-5512
Address
302 EAST PETTIGREW STREET, DURHAM, NC
Compare DTIL vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DTIL
Precision Biosciences Inc
|
7.52 | 192.23M | 34.26M | -46.61M | -62.01M | -5.1806 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Precision Biosciences Inc Stock (DTIL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-30-24 | Initiated | Guggenheim | Buy |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Jun-09-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-27-20 | Resumed | BTIG Research | Buy |
| Apr-03-20 | Downgrade | Goldman | Buy → Neutral |
| Mar-05-20 | Initiated | Stifel | Buy |
| Feb-25-20 | Initiated | William Blair | Outperform |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jul-16-19 | Initiated | H.C. Wainwright | Buy |
| Apr-22-19 | Initiated | Barclays | Overweight |
| Apr-22-19 | Initiated | Goldman | Buy |
| Apr-22-19 | Initiated | JP Morgan | Overweight |
| Apr-22-19 | Initiated | Jefferies | Buy |
View All
Precision Biosciences Inc Stock (DTIL) Latest News
Precision BioSciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
MSN Money - MSN
Precision BioSciences (DTIL) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Precision BioSciences (DTIL) Q1 2026 loss narrows as gene-editing pipeline advances - Stock Titan
Precision BioSciences 1Q 2026: Revenue $10.8M, EPS $(0.75) — 10-Q Summary - TradingView
Precision BioSciences (DTIL) posts Q1 2026 results and advances HBV and DMD gene editing - Stock Titan
DTIL: Advanced gene editing trials and improved financials, with strong cash runway through 2028 - TradingView
Precision BioSciences: Q1 Earnings Snapshot - Citizen Tribune
BRIEF-Precision BioSciences, Inc. Q1 Revenue USD 10.838 Million Vs. IBES Estimate USD 4.05 Million - TradingView
Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update - Yahoo Finance
Precision BioSciences Q1 2026 earnings preview - MSN
Precision BioSciences (DTIL) Set to Report Q1 2026 Earnings with Analyst Expectations - GuruFocus
Precision BioSciences (DTIL) Projected to Post Earnings on Tuesday - MarketBeat
Precision BioSciences to Report First Quarter 2026 Financial Results on May 5, 2026 - BioSpace
H.C. Wainwright Reaffirms Their Buy Rating on Precision BioSciences (DTIL) - The Globe and Mail
Precision BioSciences Activates First Clinical Trial Site and Begins Patient Enrollment in Phase 1/2 FUNCTION-DMD Study - BioSpace
Precision BioSciences (DTIL) Launches First Clinical Trial for P - GuruFocus
Precision BioSciences opens enrollment for DMD gene therapy trial By Investing.com - Investing.com South Africa
Precision BioSciences opens enrollment for DMD gene therapy trial - Investing.com
Precision Biosciences Activates First Clinical Trial Site and Begins Patient Enrollment in Phase 1/2 FUNCTION-DMD Study - marketscreener.com
Precision BioSciences to present DMD gene therapy data at May conference - Investing.com UK
Precision BioSciences (DTIL) Presents Promising Data on PBGENE-D - GuruFocus
Gene-editing trial update points to fewer crises in 7 infants - Stock Titan
Precision BioSciences Announces Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting - marketscreener.com
DTIL Stock Price, Quote & Chart | PRECISION BIOSCIENCES INC (NASDAQ:DTIL) - ChartMill
Should you buy Precision BioSciences (DTIL) after golden cross? - MSN
Precision BioSciences Announces Grant of Inducement Awards under Nasdaq Listing Rule 5635(4) - marketscreener.com
Precision BioSciences (DTIL) surpasses Q4 earnings and revenue estimates - MSN
Precision BioSciences announces grant of inducement awards - TipRanks
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - The National Law Review
Precision BioSciences (DTIL) Grants Inducement Award to New Empl - GuruFocus
MSN - MSN
Precision BioSciences Announces Late-Breaking Poster Presentation for PBGENE-HBV at European Association for the Study of the Liver Congress 2026 - Business Wire
DTIL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Empery Asset Management, LP Reduces Stake in Precision BioSciences Inc - GuruFocus
Precision BioSciences stock (US74019P1084): Is its gene-editing platform strong enough to unlock bio - AD HOC NEWS
Precision BioSciences reports encouraging muscle improvements in preclinical DMD gene therapy study - MSN
Precision BioSciences stock (US74019P1084): Is its gene editing platform strong enough to unlock bio - AD HOC NEWS
Precision Biosciences Inc Stock (DTIL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Precision Biosciences Inc Stock (DTIL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Amoroso Michael | President and CEO |
Feb 18 '26 |
Sale |
3.84 |
20,559 |
78,947 |
243,392 |
| Kelly John Alexander | Chief Financial Officer |
Feb 17 '26 |
Option Exercise |
0.00 |
27,584 |
0 |
134,032 |
| Kelly John Alexander | Chief Financial Officer |
Feb 18 '26 |
Sale |
3.84 |
8,149 |
31,292 |
125,883 |
| Scimeca Dario | General Counsel and Secretary |
Feb 17 '26 |
Option Exercise |
0.00 |
16,667 |
0 |
61,382 |
| Scimeca Dario | General Counsel and Secretary |
Feb 18 '26 |
Sale |
3.84 |
4,925 |
18,912 |
56,457 |
| SMITH J. JEFFERSON | Chief Research Officer |
Feb 17 '26 |
Option Exercise |
0.00 |
16,667 |
0 |
126,851 |
| SMITH J. JEFFERSON | Chief Research Officer |
Feb 18 '26 |
Sale |
3.84 |
4,925 |
18,912 |
121,926 |
1.77%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):